Phase I Study of TENPA in Advanced Solid Cancer

Advanced Solid Tumor Clinical Trial

Official title:

A Prospective, Open-label, Dose Escalation (Part A), Cohort Expansion (Part B) Phase I Study to Investigate the Safety and to Determine Maximum Tolerated Dose and Recommended Phase 2 Dose of TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel) in Patients With Advanced Solid Tumor

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02979392
• Other study ID #: H1604-140-758
• Status: Terminated
• Phase: Phase 1
• Start date: May 2, 2016
• Est. completion date: July 4, 2019

Study information

• Verified date: September 2019
• Source: Seoul National University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to investigate the safety and to determine maximum tolerated dose and recommended phase 2 dose of TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel) in patients with advanced solid tumor.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 19
• Est. completion date: July 4, 2019
• Est. primary completion date: July 4, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

1. Willing and able to provide written informed consent for voluntary participation in the trial

2. Twenty years of age or older on the day of signing informed consent

3. Advanced solid tumors with no standard treatment available

4. Evaluable disease or have measurable lesion

5. ECOG performance score of 0 or 1

6. Life expectancy = 12 weeks

7. Adequate organ and marrow function as defined below:

A. Absolute neutrophil count (ANC) = 1.5 x 109/L (> 1500 per mm3) B. Haemoglobin = 8.0 g/dL C. Platelet count = 100 x 109/L (>100,000 per mm3) D. AST (SGOT)/ALT (SGPT) = 2.5 x institutional ULN E. Serum bilirubin = 2 x institutional upper limit of normal (ULN) F. Serum creatinine = 1.5 mg/dL

8. Adequate heart function A. QT interval corrected for heart rate (QTc) = 480 ms

9. In the opinion of the investigator likely to have the willingness to comply with the study protocol during and after the study period and capable of complying with it

10. Negative serum pregnancy test (ß HCG) upon study entry and agree to use contraception

Exclusion Criteria:

1. Uncontrolled CNS metastatic disease (radiographically unstable and symptomatic disease). (note) Subjects with previously treated CNS metastases (surgery or stereotactic brain radiation therapy) that are radiographically stable for at least 4 weeks are permitted to enroll. Subjects should not receive corticosteroids within 3 weeks prior to study enrollment.

2. History of leptomeningeal carcinomatosis; brain metastasis with seizure not controlled with standard medical management.

3. Major surgery within 4 weeks: patient must have recovered from any effects of any major surgery.

4. History of hematopoietic stem cell transplantation or solid organ transplantation

5. History of Gilbert's syndrome

6. Prior malignancy except:

Basal cell carcinoma and squamous cell carcinoma of the skin that has undergone potentially curative surgery, in situ cervical cancer that has undergone potentially curative surgery and had no evidence of recurrence at least in past 3 years, other malignancy that has undergone curative surgery and had no evidence of disease at least in past 5 years.

7. Significant cardiovascular disease, such as: history of myocardial infarction, acute coronary syndrome or coronary angioplasty/stenting/bypass grafting within the last 6 months; History or current evidence of clinically significant arrhythmia or conduction disorder, except symptomatic congestive heart failure (CHR), atrial fibrillation, and paroxysmal supraventricular tachycardia (PSVT)

8. Sustained uncontrolled hypertension

9. Test results indicating active infection with human immunodeficiency virus (HIR) or hepatitis B or C, defined by positive serology testing (note) inactive hepatitis B carrier on antiviral agents are permitted to enroll.

10. Neuromuscular disorder associated with CK elevation (eg. Inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, and spinobulbar muscular atrophy)

11. Uncontrolled intercurrent illness or symptoms including, but not limited to, ongoing or active infection, bowel obstruction, psychiatric illness/social situations that would limit compliance with study requirement.

12. Radiation therapy within 2 weeks of the first dose of study drug: patient must have recovered from any effects of radiation therapy

13. Pregnant or breast feeding.

14. Female subjects of childbearing potential within the projected duration of the study, starting with the screening visit through 30 days after the last dose of study drug.

Female of childbearing potential are defined as those who are not surgically sterile (i.3., bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or who are not postmenopausal (defined as 12 months with no menses without an alternative medical cause). Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control.

15. Non-sterilized males who are sexually active with a female partner of child bearing potential from screening through 30 days after receipt of the final dose of study drug.

16. Any medical, psychiatric or cognitive disorder that compromise the ability of the subject to give informed consent, comply with the study protocol, and complete the study.

Related Conditions & MeSH terms

• Advanced Solid Tumor

Intervention

Drug:
• TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel)
TENPA IV once every 3 weeks (Phase I starting dose 75 mg/m2)

Locations

Country	Name	City	State
Korea, Republic of	Seoul National University Hospital	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Yung-Jue Bang

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose limiting toxicity (DLT)		at least one cycle of treatment (3 weeks)
Primary	Maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D)		at least one cycle of treatment (3 weeks)
Secondary	Maximum Plasma Concentration [Cmax]		3 weeks
Secondary	Area Under the Curve [AUC]		3 weeks
Secondary	Response rate (RR)		6 weeks
Secondary	Progression-free survival (PFS)		6 weeks